GlobeNewswire by notified

Van Lanschot Kempen: update on share buy-back programme 8 March 2022 – 14 March 2022


Amsterdam/’s-Hertogenbosch, the Netherlands, 15 March 2022

In the period from 8 March 2022 until 14 March 2022 Van Lanschot Kempen has repurchased 33,075 of its own shares (depositary receipts for Class A ordinary shares). The shares were repurchased at an average price of €21.47 per share for a total amount of €710,246.        

These repurchases are psart of the share buy-back programme for at most 600,000 of own shares, which was announced on 24 February 2022. The total number of shares repurchased to date is 85,518.

More information, including a detailed overview of the repurchase transactions under this programme, is available on

Media Relations: +31 20 354 45 85;
Investor Relations: +31 20 354 45 90;

About Van Lanschot Kempen
Van Lanschot Kempen, a wealth manager active in Private Banking, Investment Management and Investment Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. As a sustainable wealth manager with a long-term focus, Van Lanschot Kempen proactively seeks to prevent negative impact for all stakeholders and to create positive long-term financial and non-financial value. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737. To fully leverage the potential of the Van Lanschot Kempen organisation for its clients, it provides solutions that build on the knowledge and expertise across its entire group and on its open architecture platform. Van Lanschot Kempen is convinced that it is able to meet the needs of its clients in a sustainable way by offering them access to the full range of its products and services across all its businesses.

For more information, please visit

This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action.

This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc’s share buybacks 17/05/202218.5.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18/05/2022 at 08:30 am Sampo plc’s share buybacks 17/05/2022 On 17/05/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)28,56046.33AQEU41,30446.31CEUX10,74946.33TQEX61,23946.32XHELTOTAL141,85246.32 *rounded to two decimals On 30 March 2022, Sampo announced a share buyback programme of up to a maximum of EUR 250 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 31 March 2022, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 4,961,994 Sampo A shares representing 0.92 per cent of the total number of shares in Sampo plc. Details

Bavarian Nordic skal producere de første frysetørrede doser af koppevaccinen efter udnyttelse af kontraktoption af den amerikanske regering18.5.2022 07:25:16 CEST | pressemeddelelse

Optioner på USD 119 mio. er udnyttet med henblik på produktion af frysetørret JYNNEOS® i 2023 og 2024Disse udgør de første optioner ud af en samlet kontrakt på USD 299 mio., der er beregnet til konvertering af eksisterende råvaccine, der allerede er indkøbt af BARDA, til ca. 13 mio. frysetørrede doser JYNNEOS KØBENHAVN, Danmark, 18. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Office of the Assistant Secretary for Preparedness and Response ved U.S. Department of Health and Human Services, har udnyttet de første optioner i kontrakten på frysetørret JYNNEOS® koppevaccine, hvorved de første doser af denne formulering vil blive produceret og faktureret i 2023 og 2024. Optionerne har en værdi af USD 119 mio., og er de første optioner, der er udnyttet med henblik på at færdigproducere den råvaccine, der allerede er fremstillet og faktureret under tidligere kontrakter med BARDA, som frysetørret JYNNEOS

Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government18.5.2022 07:25:16 CEST | Press release

USD 119 million option exercised for the manufacturing of freeze-dried JYNNEOS® in 2023 and 2024This represents the first set of options with a total value of USD 299 million to convert the existing bulk vaccine, previously purchased by BARDA, to approximately 13 million freeze-dried JYNNEOS doses COPENHAGEN, Denmark, May 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the first options under the contract to supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024. The options have a value of USD 119 million and represent the first options exercised to convert bulk vaccine, which has already been manufactured and invoiced under previous contracts with BARDA,

Norrlandsfonden supports Copperstone Resources with funds18.5.2022 07:15:00 CEST | Press release

Kiruna May 18, 2022 Norrlandsfonden will invest further MSEK5.5 in a convertible debenture in Copperstone Resources AB (“Copperstone” or “the Company”). In accordance with the existing loan agreement in connection with fund raisings, Norrlandsfonden has the right, but not obligation, to invest in Copperstone. The credit facilities are agreed at Stibor 90 + 5 percent annually, with quarterly interest payments. Norrlandsfonden is entitled to convert parts of the, or the entire, amount until April 30, 2027. The conversion prices shall be 1.54 SEK/share, corresponding to a 40 percent premium from the volume weighted average of the recent directed equity issues at approximately 1.1 SEK per share. At full conversion of the debenture, Norrlandsfonden would receive 3,571,428 shares of Copperstone, corresponding to a dilution of 0.3%. “We are very pleased and proud that Norrlandsfonden once again has decided to support Copperstone. The increased working capital comes in very handy now that also

Norrlandsfonden investerar i Copperstone Resources18.5.2022 07:15:00 CEST | Pressemelding

Kiruna den 18 maj 2022 Norrlandsfonden har valt att investera ytterligare 5,5 MSEK i ett konvertibelt skuldebrev i Copperstone Resources AB (”Copperstone” eller ”Bolaget”). I enlighet med existerande låneavtal äger Norrlandsfonden rätt, men inte skyldighet, att stödja Copperstone i samband med kapitalanskaffningar. Lånet löper med Stibor 90 + 5 procents årlig ränta med kvartalsvisa räntebetalningar. Norrlandsfonden äger rätt att fram till den 30 april 2027 påkalla konvertering av hela eller delar av det nominella beloppet. Konverteringspriset kommer uppgå till 1,54 SEK/aktie, motsvarande 40 procents premium mot det volymvägda genomsnittet på de senaste riktade aktieemissionerna på cirka 1,1 SEK/aktie. Vid full konvertering av detta konvertibla skuldebrev skulle Norrlandsfonden erhålla 3 571 428 aktier i Copperstone, motsvarande 0,3 procents utspädning för befintliga aktieägare. “Vi är väldigt glada och stolta att Norrlandsfonden ännu en gång har beslutat att investera i Copperstone och